CClinicalTrials.gg
CompletedNCT03399136FLEXUpdated Dec 6, 2022

Fitness and Longevity in Exercise

An interventional study of Exercise training in HIV-1-infection and Aging, sponsored by University of Maryland, Baltimore. Completed. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2022-12-06.

Sponsored by University of Maryland, Baltimore · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
31
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Study summary

The study objective was to determine the safety and efficacy of aerobic exercise in older HIV-infected men in a randomized trial comparing different levels of exercise intensity.

Read the detailed description

The study was a randomized trial of moderate-intensity versus high-intensity aerobic exercise (AEX) training in older HIV-infected adults. Funding was provided by K23 AG024896 (PI, Oursler) and the UMB Claude D. Pepper Older Americans Independence Center P60 AG12583 (PI, Goldberg).

The central hypothesis was that high-intensity AEX training is well-tolerated and significantly increases aerobic capacity in older HIV-infected adults.

The study met its objectives:

  1. Scientific AIMS met:

    1. High-intensity AEX training significantly increases aerobic capacity
    2. Both moderate-intensity and high-intensity AEX training improve ambulatory function and endurance.
    3. Activity of skeletal muscle oxidative enzymes is reduced, and associated with aerobic capacity.
  2. Feasibility Objectives met:

    1. AEX training is safe and well-tolerated in older HIV-infected adults.
    2. Skeletal muscle punch biopsy is safe and well-tolerated in older HIV-infected adults.
    3. Preliminary data was collected on plasma biomarkers of inflammation.
02

Conditions studied

  • HIV-1-infection
  • Aging

Keywords

  • Exercise training
  • Intervention
  • Aerobic capacity
03

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • HIV+
  • stable combination antiretroviral therapy (cART)

Exclusion criteria

Exclusion Criteria:

  • AIDS defining conditions in the prior six months
  • Conditions that increase the risk of exercise training per the American College of Sports Medicine (ACSM)
04

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Care provider, Outcomes assessor)
Enrollment
31 participants (actual)

Study arms

  • Experimental
    Moderate-intensity aerobic exercise

    In the moderate-intensity aerobic exercise group, participants performed a self-paced 1-mile walk (3-5 METs) on an indoor track in the same exercise center as the high-intensity exercise group. Initial sessions lasted 20-30 minutes and were increased weekly to 45 minutes in parallel to the duration of the high-intensity exercise group.

    Behavioral: Exercise training

  • Experimental
    High-intensity aerobic exercise

    In the high-intensity aerobic exercise group, exercise training was performed on a motorized treadmill with occasional substitution with the elliptical machine as needed for joint pain. Target heart rate was based on the baseline treadmill test and was calculated as percentage of the heart rate reserve (HRR=maximal HR-resting HR). Initially, participants trained for 20-30 minutes at 50-60% of HRR. Duration and intensity was increased by 10% weekly so that within 5-7 weeks the aerobic exercise sessions lasted 30-45 minutes at 70-85% of HRR and at the end of the 16 weeks lasted 40-45 minutes at 75-90% of HRR.

    Behavioral: Exercise training

Interventions

  • BehavioralExercise training

    Participants attended center-based exercise sessions three times per week at the research exercise training facility located at the Baltimore VA Medical Center. All exercise training was performed under the supervision of research exercise physiologists. Heart rate (HR) was measured continuously during each session using a Polar HR watch and chest strap allowing for assessment and maintenance of treatment fidelity. Exercise logs included details on exercise type, duration, time in target heart rate zone, blood pressure and perceived intensity during each training session.

05

What researchers measure

Primary outcomes

  1. Change from baseline Cardiorespiratory Fitness at 16 weeks

    Cardiorespiratory Fitness measured by VO2peak

    Time frame: 16-weeks

Secondary outcomes

  1. Change from baseline Six-minute walk distance at 16 weeks

    Distance walked at normal pace in 6 minutes

    Time frame: 16-weeks

  2. Change from baseline body composition at 16 weeks

    body composition measured as total and regional lean tissue and fat mass (DXA)

    Time frame: 16-weeks

  3. Change from baseline exercise endurance at 16 weeks

    exercise endurance measured as time on treadmill during modified Bruce protocol

    Time frame: 16-weeks

Other outcomes

  1. skeletal muscle oxidative function

    activity of enzymes in oxidative function from muscle biopsy

    Time frame: baseline

06

Study locations

No study locations are listed for this record.

07

References and documents

Publications

  • Ortmeyer HK, Ryan AS, Hafer-Macko C, Oursler KK. Skeletal muscle cellular metabolism in older HIV-infected men. Physiol Rep. 2016 May;4(9):e12794. doi: 10.14814/phy2.12794. PubMed 27166139 ↗

Individual participant data

Plan to share: No — Data, which include PHI, are available from the University of Maryland School of Medicine Institutional Review Board for researchers who meet the criteria for access to confidential data.

08

Registry details

Key details

Study ID
NCT03399136
Lead sponsor
University of Maryland, Baltimore
Responsible party
KrisAnn Oursler (Physician, University of Maryland, Baltimore) — Principal investigator
First posted
Jan 16, 2018
Start date
Jul 19, 2007
Primary completion
Oct 29, 2010
Completion
Apr 23, 2012
Last update
Dec 6, 2022

Study contacts

Krisann Oursler, MD
principal investigator · University of Maryland, Baltimore

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion